Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone. Human research is old and small, while unregulated use has generated important safety concerns.
Key points
- The compound is a cyclic heptapeptide analogue of alpha-MSH with activity at several melanocortin receptor subtypes.
- Evidence from cells, animals and humans must be interpreted separately.
- Not authorised by the MHRA as a medicine. UK regulators have warned consumers about unlicensed melanotan products.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone. Human research is old and small, while unregulated use has generated important safety concerns. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Melanocortin receptor activity can influence pigmentation and central physiological pathways. Receptor non-selectivity helps explain why early studies reported effects beyond pigmentation.
What does the current evidence show?
- A Phase 1 pilot involved only three men and reported increased pigmentation alongside nausea, fatigue, yawning and spontaneous erections.
- A later crossover study in ten men examined erectile responses and reported frequent nausea.
- Case reports and regulator warnings describe concerns associated with unlicensed melanotan products, but case reports cannot quantify incidence.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Early trials were extremely small and not designed to establish long-term safety.
- Product identity and contamination are separate risks in unregulated material.
- Changes in pigmentation may complicate assessment of skin lesions; causality for longer-term outcomes remains unresolved.
Regulatory and safety context
Not authorised by the MHRA as a medicine. UK regulators have warned consumers about unlicensed melanotan products. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.